Abstract
The Disrupted-in-schizophrenia 1 (DISC1) protein is a key regulator at the intersection of signaling pathways relevant for adaptive behavior. It is prone to posttranslational changes such as misassembly and aggregation but the significance of such transformations for human mental illness has remained unclear.
Here we demonstrate that DISC1 protein aggregates are increased in CSF samples of patients with first episode psychosis (n=50) compared to healthy controls (n=47), as measured by the highly sensitive surface-based fluorescence intensity distribution analysis technology that enables single aggregate detection. The concentration was in the low femtomolar range. No correlations were found to symptom levels, but the difference was particularly significant in the subset of patients receiving the diagnoses “schizophrenia, unspecified” (DSM IV 295.9) or schizoaffective disorder (DSM IV 295.70) at 18-month follow-up.
The occurrence of protein aggregates in vivo in patients with psychotic disorders has not been previously reported. It underscores the significance of posttranslational modifications of proteins both as pathogenetic mechanisms and as potential diagnostic markers in these disorders.
Competing Interest Statement
The authors declare no competing non-financial interests but the following competing financial interests: DW and OB are shareholders of attyloid GmbH. All other authors declare no competing financial interests related to this work.
Funding Statement
C.K. was supported by a grant from the DFG 1679/14-1. The study was further supported by the Swedish Research Council (Grant No. 523-2014-3467 (SC), Erling Persson Foundation (CMS), 2021-02251_VR (SE), 2019-01452_VR (GE)), Karolinska Institutet and Stockholm County Council (20160328, 20180487 [SC], (20190175) [SE], 20190447 [CMS]). Development of the sFIDA technology was supported by the programs Biomarkers Across Neurodegenerative Diseases I + II of The Alzheimer's Association, Alzheimer's Research UK and the Weston Brain Institute (11084 and BAND-19-614337). We are also grateful for support from The Michael J. Fox Foundation for Parkinson's Research (14977, 009889), from the ALS Association and from the Packard Center (19-SI-476)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the Regional Ethics Committee in Stockholm (2010/879-31-1 with amendments)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. For image data analysis, we used the sFIDAta software tool, which can be made available upon request from the corresponding author
